Video

Q&A With Gary Franklin, MD, MPH, FAAN, of the University of Washington: The Opioid Epidemic: Where Do We Go From Here?

Author(s):

The opioid epidemic began nearly 30 years ago and since that time small steps have been taken to reverse its effects. The question remains whether too much damage has already been done to fix the problems in a timely manner.

The opioid epidemic began nearly 30 years ago and since that time small steps have been taken to reverse its effects. The question remains whether too much damage has already been done to fix the problems in a timely manner.

Gary Franklin, MD, MPH, FAAN, from the University of Washington discussed what needs to be done to ensure patients get the care they need without becoming addicted to opioid medications during the American Academy of Neurology's annual meeting in Washington DC. Franklin noted that even the opioid meciations that have been developed to protect against abuse have not made a significant impact in stopping the spread of the epidemic.

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
© 2024 MJH Life Sciences

All rights reserved.